Welcome to our dedicated page for Acceleron news (Ticker: XLRN), a resource for investors and traders seeking the latest updates and insights on Acceleron stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acceleron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acceleron's position in the market.
Acceleron Pharma (Nasdaq:XLRN) reported a net loss of $39.2 million for Q3 2020, with revenues of $22.6 million attributed to REBLOZYL royalties. There was significant growth in REBLOZYL sales, achieving $96 million in net sales, up from $55 million in Q2 2020. The company highlighted progress in clinical trials, including the upcoming STELLAR Phase 3 trial for sotatercept in pulmonary arterial hypertension (PAH). With $887.4 million in cash reserves, Acceleron believes it can sustain operations and support its research and commercialization goals.
Acceleron Pharma reported net sales of REBLOZYL (luspatercept-aamt) at approximately $96 million for Q3 2020, a significant increase from the previous quarter's $55 million. The company's royalty revenue is projected at $19.3 million, up from $11.1 million in Q2 2020. Full financial results will be announced later today. Acceleron collaborates with Bristol Myers Squibb on REBLOZYL and is developing sotatercept for pulmonary arterial hypertension (PAH), with upcoming Phase 3 trials planned.
Acceleron Pharma Inc. (Nasdaq: XLRN) announced the presentation of six clinical abstracts on REBLOZYL (luspatercept-aamt) at the upcoming 62nd ASH Annual Meeting & Exposition, December 5-8, 2020. Key studies include updates from Phase 3 trials MEDALIST and BELIEVE, showing significant improvements in quality of life and reductions in red blood cell transfusion requirements for patients treated with luspatercept. These findings highlight the therapeutic potential of REBLOZYL in treating lower-risk myelodysplastic syndromes and beta-thalassemia.
Acceleron Pharma Inc. (Nasdaq:XLRN) announced a webcast and conference call on November 5, 2020, at 5:00 p.m. EST. This call will cover the company’s third quarter 2020 operating and financial results. Participants can join by dialing 877-312-5848 for domestic calls or 253-237-1155 for international calls. The company focuses on developing therapeutics for serious and rare diseases, with REBLOZYL® for blood disorders and sotatercept for pulmonary arterial hypertension. The archived webcast will be available for replay shortly after the event.
Bristol Myers Squibb Canada and Acceleron Pharma (NASDAQ:XLRN) have received approval from Health Canada for REBLOZYL® (luspatercept), the first erythroid maturation agent for treating adults with red blood cell transfusion-dependent anemia due to beta-thalassemia. This significant advancement offers a new treatment option that may reduce the need for regular transfusions, enhancing the quality of life for patients. The approval is based on the phase 3 BELIEVE study, which showed a 21.4% reduction in transfusion burden with REBLOZYL® compared to 4.5% for the placebo (P<0.001).